Modern Slavery Statement

Cancer Research UK Modern Slavery Transparency Statement - September 2016

Introduction to Cancer Research UK

Cancer Research UK is the world’s leading cancer charity dedicated to saving lives through research. We rely on the generosity of the public to fund this research through donations, buying goods in our shops or on-line and taking part in a wide range of fundraising events.

This statement is made pursuant to section 54 of the Modern Slavery Act 2015. It constitutes CRUK’s slavery and human trafficking statement for the financial year ended 31 March 2016. It covers the activities of Cancer Research UK and its wholly-owned subsidiaries: Cancer Research UK Trading Limited and Cancer Research Technology Limited.

Our Supply Chain

The Charity uses a wide range of suppliers who supply goods for sale, provide services at events and support the operations of the Charity. These include a small number of suppliers, direct or indirect, in countries deemed to be higher risk, based on the Global Slavery Index.

Policies and procedures are in place aiming to minimise the risk of modern slavery in our supply chain. Specifically, a Working with Suppliers and Partners Policy, which sets out requirements for buying goods and services; a Responsible Procurement Policy covering issues of human rights, child and forced labour and modern slavery, forming part of our contractual relationship with suppliers; and a Whistleblowing Policy that encourages staff to report any concerns including specific reference to modern slavery and child and forced labour.

Detailed due diligence is carried out on those suppliers where there may be a modern slavery risk. This includes a requirement for new suppliers to complete a modern slavery questionnaire and to provide a satisfactory audit report carried out by an independent, accredited auditor. An annual audit report, as part of ongoing supplier monitoring procedures, is also required.

Training is provided to those teams responsible for managing contractual relationships and detailed training on modern slavery risks is provided to those teams involved in purchasing goods from countries where there may be a greater risk.


This statement has been approved by the Trustees of Cancer Research UK and the Boards of Directors of Cancer Research UK Trading Limited and Cancer Research Technology Limited and signed on their behalf.

 Niamh O'Sullivan, Company Secretary, Cancer Research UK, Ian Kenyon, Director, Cancer Research UK Trading Limited, Keith Blundy, Director, Cancer Research Technology Limited

Share this page